
The Supply Chain Evolution: How To Deploy AI Successfully
AI is revolutionizing employee resource planning (ERP) systems and supply chain operations by making them more intelligent, predictive and autonomous. Because of its growing role in day-to-day business, AI is much more than an add-on; for many companies, it's becoming the backbone of supply chain management.
While challenges and roadblocks still exist, the rollout and nuances of AI applications are prompting a shift in how companies think and operate. To stay ahead, companies must adopt innovative approaches that streamline processes and improve operations throughout the supply chain.
Knowing this, the question isn't if you should adopt AI but how you can lead the charge. Being a trailblazer means being willing to explore this tool's full potential, experiment boldly and rethink what's possible.
Addressing AI-Related Deployment Challenges
When rolling out AI, it's important for companies to consider the hurdles they might face, including these three potential challenges.
For some AI and generative AI tools, a lack of clarity exists around the inputs the software requires to perform its capabilities. AI's opacity, often referred to as the "black box" problem, stems from the complexity of its neural networks. Data fed into these systems passes through layers of hidden nodes, performing thousands of computations that are largely inscrutable.
This uncertainty is precisely why AI must operate under human oversight, with clear guardrails to define its appropriate use. As Boston Consulting Group noted, human supervision is essential to managing the risks associated with generative AI, but it isn't enough on its own. It must be paired with thoughtful design and well-defined processes that help people detect and de-escalate issues when they arise.
While continued economic uncertainty, policy changes and market fluctuations impact far more than just AI implementation, they do play a large part in how successful this tech rollout may be. Take a look at the ups and downs of the market from recent trade wars.
Plus, other potential challenges like natural disasters and supplier issues remain. AI's predictive models can struggle to account for uncommon or rapidly evolving events, which could lead to gaps in forecasting accuracy and delayed response strategies.
Organizations can incorporate flexible contingency strategies to help with this. For example, a flexible contingency strategy might include a diversified supply chain with backup vendors in various regions. Coupled with AI-based scenario planning, this tactic can help companies respond to natural disasters, policy changes or supplier challenges. Pre-vetted alternatives and adaptive workflows help businesses pivot quickly during unforeseen circumstances.
By combining AI capabilities with proactive risk management, organizations can better navigate market fluctuations and maintain operational reliability in an increasingly complex global landscape.
Another potential roadblock is having the right team in place for implementation, both internally and externally, and identifying who will run point on ongoing fine-tuning and maintenance of the AI models after deployment. Bain & Company found 44% of executives surveyed lack in-house AI expertise, which is slowing its adoption.
Overlooking who runs AI leads to challenges with ownership and managing time-sensitive updates or fixes. Addressing this means bringing in or developing people who truly understand AI, can question its outputs and spot issues like hallucinations or bias before they become problems. Without this level of talent, businesses risk losing control over their AI systems, which can compromise reliability and performance as well as trust from stakeholders.
Best practices and guardrails are also crucial for maintaining strong AI governance. Strategies like requiring chain-of-thought explanations from AI tools help enhance transparency and accountability. What's more, establishing well-thought-out verification processes ensures AI insights effectively support decision making.
Ultimately, overcoming challenges and ensuring sustained success with AI requires skilled human oversight and strong governance measures that extend well beyond an organization's initial implementation.
Bridging Today's Capabilities With Tomorrow's Innovations
I believe AI's role in the supply chain is poised for a significant transformation, evolving from a decision-support tool to a more autonomous platform capable of proactively recommending actions across areas such as forecasting, planning and delivery. As AI continues to evolve, I expect organizations to lean on it more to simplify day-to-day operations, cut down on repetitive manual tasks and boost accuracy in forecasting and planning. This shift toward AI-driven decision making will reshape conventional supply chain management approaches. It could also pave the way for smarter and more adaptable logistics strategies.
Businesses can start by trialing one or two high-impact AI integrations, like demand forecasting or logistics optimization, and gradually expand their scope. Doing so can allow them to modify their AI implementations while addressing the challenge of building a talent pipeline. The key is to prioritize strategic AI adoption. Companies may also consider using cloud-based advancements to integrate current capabilities with future innovations.
Final Thoughts
There's no doubt that AI's integration into supply chain management and logistics operations is reshaping business. Whether it's helping to redesign processes or improve how industry leaders forecast and make decisions, AI is helping boost efficiency, accuracy and agility.
These tools can help companies anticipate disruptions by streamlining operations and providing elevated insights to inform decision making in an increasingly complex world. The journey isn't without its hurdles, but they are also signs that it's time to evolve. Roadblocks are opportunities for improvement, and companies integrating AI into their ERP and supply chain operations wisely can position themselves for lasting competitive success.
Forbes Business Council is the foremost growth and networking organization for business owners and leaders. Do I qualify?

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
Gold Surges to $3350 as Tariffs and Weak Jobs Data Rattle Markets
Happy Friday, traders. Welcome to our weekly market wrap, where we take a look back at these last five trading days with a focus on the market news, economic data, and headlines that had the most impact on gold prices and other key correlated assets— and may continue to in the future. Here's what you need to know: Gold spot prices surged to $3350/oz Friday after a weak Jobs Report and new tariffs triggered a market shock. Earlier in the week, gold briefly dipped below $3300/oz amid Fed uncertainty and profit-taking. The Fed held rates steady but hinted that future moves depend on inflation and tariff-driven risks. Volatility is expected to carry over into next week due to limited economic data and elevated uncertainty. So, What Kind of a Week Has it Been? Financial markets, both as a technical marketplace and as a mass of people, appeared to be riding the waves pretty smoothly for much of this week. Those waves being one of the highest profile weeks, from a macroeconomic data perspective, in some time, as well as the potential pivot-points of the July FOMC meeting and the enactment of another raft of Trump Tariffs against many of the US' foundational trading partners. Gold Slides Early, Then Spikes For gold specifically, trading in the first days of the week was frothy at times as traders positioned themselves for mid-week fireworks and made liquidations to lock in profits before closing the book of business for July. On net, the yellow metal slid slightly lower during these sessions but appeared to have healthy support and ultimately traded comfortably in a band between $3320-3330/oz in the spot market. Very early Wednesday morning, as managers and investors prepared for the FOMC announcement (and, to a lesser extent, the first-look at US GDP for Q2,) gold endured the sharpest sell-off of the week, breaking down support and taking spot below $3300 just before the US cash-market opened and continuing to slide to the weekly nadir at $3270/oz. FOMC Holds Steady, Market Digests The FOMC's July announcement was delivered largely as expected: No rate cut yet, to the chagrin of the US administration among others, and a refusal to directly suggest that a cut in September (to say nothing of the Jackson Hole summit this month) is anything more than a possibility while pointing to the potential inflationary effects of the US' Trump Tariff policy clicking into effect in August as the main reason for needing to 'wait and see.' Gold prices reacted with a moderate rebound, although any rally higher for the precious metal was going to be muted by headwinds following on from the Fed announcement (recall, much of gold's upward mobility in 2025 has been based on an expectation of lower rates.) When Asian markets opened for Thursday's trading, however, the chop-and-change as traders unwound pre-FOMC positions or otherwise locked in positions and/or profits ahead of both month-end and the eleventh hour before the US' threatened trade restrictions had an unexpected effect of pushing gold higher. The yellow metal peeked briefly back above $3300 before the start of US trading, and another US Dollar rally wound gold back to the neighborhood of $3290. Jobs Report Shock and Tariffs Ignite a Rally From here, it looked as if gold would end up closing the week at a moderate loss between Sunday evening's opening bids and Friday's close. But the double-whammy of a slew of the Trump Administration's punitive tariff rates going into effect as of August 1, combined with a very ugly July Jobs Report, has tripped markets into a powder keg. The resulting explosion in volatility has shot gold spot prices sharply higher. July's Non-Farm Payrolls data, expected to show +100K jobs added to the US economy, instead came in at a disappointing 73K while also making drastic downward revisions to the prior two months' reporting. This, as much as anything, has been the catalyst for gold's aggressive spike to end the week, quickly jumping $40/oz to $3340 minutes after the print before picking up another +$10/oz once US markets opened. The primary signals here were clear pluses for gold as an asset. On one hand, gold benefits from the inherent shock of instability and uncertainty the Jobs Report has flushed into markets (which has, at the same time, rocked equities lower.) On the other hand, the dominant read of this data is that it piles much stronger pressure on the Fed to begin easing conditions by cutting rates, another boon for gold. What's Next? This shock has been so acute and aggressive, and has come so close to the end of the week, that it is likely we will see momentum carry on when markets reopen on Sunday evening. If it can hold serve, we may see more risk-off rebalancing into gold positions as the calendar ahead is much, much lighter on consequential macro data. In the meantime, traders, I hope you can get out and safely enjoy your weekend for the next couple of days. After that, I'll see you back here next week for another market recap. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
13 minutes ago
- Yahoo
Flora Growth Corp. (FLGC) Reports Q2 Loss, Tops Revenue Estimates
Flora Growth Corp. (FLGC) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.22 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -83.33%. A quarter ago, it was expected that this company would post a loss of $0.01 per share when it actually produced a loss of $0.04, delivering a surprise of -300%. Over the last four quarters, the company has not been able to surpass consensus EPS estimates. Flora Growth, which belongs to the Zacks Medical - Products industry, posted revenues of $14.8 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 25.71%. This compares to year-ago revenues of $15.68 million. The company has topped consensus revenue estimates just once over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Flora Growth shares have lost about 42.9% since the beginning of the year versus the S&P 500's gain of 7.8%. What's Next for Flora Growth? While Flora Growth has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Flora Growth was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.06 on $12.52 million in revenues for the coming quarter and -$0.40 on $47.63 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Products is currently in the bottom 26% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Another stock from the same industry, Allurion Technologies, Inc. (ALUR), has yet to report results for the quarter ended June 2025. This company is expected to post quarterly loss of $0.65 per share in its upcoming report, which represents a year-over-year change of -360%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Allurion Technologies, Inc.'s revenues are expected to be $5.95 million, down 49.5% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Flora Growth Corp. (FLGC) : Free Stock Analysis Report Allurion Technologies, Inc. (ALUR) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
13 minutes ago
- Yahoo
Here's What Key Metrics Tell Us About Moderna (MRNA) Q2 Earnings
For the quarter ended June 2025, Moderna (MRNA) reported revenue of $142 million, down 41.1% over the same period last year. EPS came in at -$2.13, compared to -$3.33 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $127.17 million, representing a surprise of +11.66%. The company delivered an EPS surprise of +28.76%, with the consensus EPS estimate being -$2.99. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance. Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance. Here is how Moderna performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Product sales- United States: $88 million versus the three-analyst average estimate of $28.31 million. The reported number represents a year-over-year change of -45.7%. Product sales- Rest of world: $26 million compared to the $42.95 million average estimate based on two analysts. The reported number represents a change of +18.2% year over year. Revenue- Net Product sales: $114 million versus $81.42 million estimated by eight analysts on average. Compared to the year-ago quarter, this number represents a -38% change. Revenue- Other revenue: $28 million versus the six-analyst average estimate of $25.13 million. The reported number represents a year-over-year change of -50.9%. Revenue- Other revenue- Grant revenue: $5 million compared to the $6.16 million average estimate based on three analysts. Revenue- Other revenue- Licensing & royalty revenue: $2 million versus $10.65 million estimated by two analysts on average. Revenue- Other revenue- Collaboration revenue: $4 million versus the two-analyst average estimate of $7.5 million. View all Key Company Metrics for Moderna here>>> Shares of Moderna have returned -3.1% over the past month versus the Zacks S&P 500 composite's +2.3% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Moderna, Inc. (MRNA) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data